Charles Fogarty is a Respiratory physician affiliated with Spartanburg Regional Medical Center. OpenAlex indexes 100 publications with 3,464 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2030 N Church Place
Spartanburg, SC 29303
Telephone
864-558-2685Registry record last updated 11 Jun 2012.
Clinical trials
- Nasal Swab Study to Explore the Nasal Microbia
Sponsor: Kimberly-Clark Corporation
- Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
Sponsor: Elcelyx Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Calyxo, Inc.Program year20252 payments
- Electromed, Inc.Program year202512 payments
- Axsome Therapeutics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%beta2-Adrenergic Agonist66.7%Albuterol Sulfate Hfa100%Part D<11 patientsCorticosteroid33.3%Symbicort100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial
Journal of Allergy and Clinical Immunology
2024 - Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial
The Journal of Infectious Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”